F8
ENSG00000185010
Target class
Secreted protein
Chromosome
X
Approved drugs
13
Clinical candidates (approved and in development)
16
- Approved drugs
- 13
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 16
- Chemical probe available
- No
- Target name
- F8
- Gene name
- Coagulation factor VIII
- Gene symbol
- F8
- Previous gene symbols
- F8C
- Protein name
- Coagulation factor VIII (Antihemophilic factor) (AHF) (Procoagulant component) [Cleaved into: Factor VIIIa heavy chain, 200 kDa isoform; Factor VIIIa heavy chain, 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain]
- FVIII
- DXS1253E
- HEMA
- Gene biotype
- Protein coding
- Gene family
- Multicopper oxidase family
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 53
- Highest tissue expression
- 19.65
- Tissue specificity (Gini)
- 0.395
- Tissue specificity (tau)
- 0.728
- KEGG gene identifiers
- hsa:2157
- Protein interaction confidence
- 0.882704
- Protein interaction partners
- 27
- R-HSA-114608
- R-HSA-163841
- R-HSA-204005
- R-HSA-5694530
- R-HSA-9672383
- R-HSA-9672387
- R-HSA-9672391
- R-HSA-9672393
- R-HSA-9672395
- R-HSA-9672396
- R-HSA-9672397
- R-HSA-9673202
- R-HSA-9674519
- R-HSA-9769735
- R-HSA-9769739
- R-HSA-9769743
- End position
- 155026940
- Start position
- 154835788
- Chromosome
- X
- Strand
- Reverse
- Secreted, extracellular space.
- Tissue specificity (tau)
- 0.728408
- Expression inequality (Gini)
- 0.394591
Expression in transcripts per million
- Adipose - Visceral (Omentum)
- 19.65
- Adipose - Subcutaneous
- 15.74
- Heart - Atrial Appendage
- 13.51
- Breast - Mammary Tissue
- 12.64
- Ovary
- 12.57
Expression in transcripts per million
- Adipose - Visceral (Omentum)19.65
- Adipose - Subcutaneous15.74
- Heart - Atrial Appendage13.51
- Breast - Mammary Tissue12.64
- Ovary12.57
- Uterus11.53
- Heart - Left Ventricle10.76
- Spleen10.65
- Thyroid9.73
- Esophagus - Muscularis9.42
- Lung8.93
- Artery - Coronary8.83
- Nerve - Tibial8.72
- Cervix - Endocervix8.13
- Esophagus - Gastroesophageal Junction7.96
- Adrenal Gland7.8
- Fallopian Tube7.67
- Colon - Sigmoid6.73
- Muscle - Skeletal6.27
- Prostate6.11
- Bladder5.83
- Brain - Frontal Cortex (BA9)5.59
- Testis4.97
- Kidney - Cortex4.72
- Pituitary4.32
And 29 more, listed on the interactive page.
Biological processes
- GO:0007596
- GO:0005576
- GO:0005788
- GO:0005796
- GO:0005886
- GO:0030134
- GO:0031093
- GO:0033116
Molecular functions
- GO:0005515
Related records
Trials (519)
- "LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia
- 5-MTHF Supplementation for Treatment of Type 1 Diabetes Patients
- A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
- A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
- A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.
- A Clinical Study on the Improvement of Sleep Quality, Skin Condition and Life Status After Taking Sleep Aid Drinks
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
- A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
- A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
- A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
- A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
- A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
- A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers
- A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
- A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD
- A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma
- A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus
Drugs (16)
- Antihemophilic factor, pegylated (MW 20000) human sequence recombinant Coagulation factor VIII exogenous protein
- Damoctocog alfa pegol Coagulation factor VIII exogenous protein
- Drotrecogin alfa (activated) Coagulation factor VIII inhibitor
- Efanesoctocog alfa Coagulation factor VIII exogenous protein
- Efmoroctocog alfa Coagulation factor VIII exogenous protein
- Giroctocogene fitelparvovec Coagulation factor VIII exogenous gene
- Human coagulation factor VIII Coagulation factor VIII exogenous protein
- Lonoctocog alfa Coagulation factor VIII exogenous protein
- Moroctocog alfa Coagulation factor VIII exogenous protein
- Octocog alfa Coagulation factor VIII exogenous protein
- Omfiloctocog alfa Coagulation factor VIII exogenous protein
- Simoctocog alfa Coagulation factor VIII exogenous protein
- Susoctocog alfa Coagulation factor VIII exogenous protein
- TB-402 Coagulation factor VIII inhibitor
- Turoctocog alfa Coagulation factor VIII exogenous protein
- Turoctocog alfa pegol Coagulation factor VIII exogenous protein